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Abstract
Background: Astrocyte activation is a hallmark of traumatic brain injury resulting in neurological dysfunction or
death for an overproduction of inflammatory cytokines and glial scar formation. Both the silent mating type
information (Sirt1) expression and mitogen-activated protein kinase (MAPK) signal pathway activation represent
a promising therapeutic target for several models of neurodegenerative diseases. We investigated the potential
effects of Sirt1 upregulation and MAPK pathway pharmacological inhibition on astrocyte activation in vitro and
in vivo. Moreover, we attempted to confirm the underlying interactions between Sirt1 and MAPK pathways in
astrocyte activation after brain injury.
Methods: The present study employs an interleukin-1β (IL-1β) stimulated primary cortical astrocyte model in vitro and
a nigrostriatal pathway injury model in vivo to mimic the astrocyte activation induced by traumatic brain injury.
The activation of GFAP, Sirt1, and MAPK pathways were detected by Western blot; astrocyte morphological hypertrophy
was assessed using immunofluorescence staining; in order to explore the neuroprotective effect of regulation
Sirt1 expression and MAPK pathway activation, the motor and neurological function tests were assessed after injury.
Results: GFAP level and morphological hypertrophy of astrocytes are elevated after injury in vitro or in vivo. Furthermore,
the expressions of phosphorylated extracellular regulated protein kinases (p-ERK), phosphorylated c-Jun N-terminal kinase
(p-JNK), and phosphorylated p38 activation (p-p38) are upregulated, but the Sirt1 expression is downregulated.
Overexpression of Sirt1 significantly increases the p-ERK expression and reduces the p-JNK and p-p38 expressions.
Inhibition of ERK, JNK, or p38 activation respectively with their inhibitors significantly elevated the Sirt1 expression
and attenuated the astrocyte activation. Both the overproduction of Sirt1 and inhibition of ERK, JNK, or p38 activation
can alleviate the astrocyte activation, thereby improving the neurobehavioral function according to the modified
neurological severity scores (mNSS) and balance latency test.
Conclusions: Thus, Sirt1 plays a protective role against astrocyte activation, which may be associated with the
regulation of the MAPK pathway activation induced by brain injury in vitro and in vivo.
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Background
Traumatic brain injury can be a serious insult caused
by a wide variety of stimuli, enclosing a large range of
severities [1]. These severities not only induce direct
and immediate neuronal injury but also have the potential
for long-term and gradually evolving sequelae, such as
overactivation of glial cells and secretion of circulating leu-
cocytes around the lesion site, contributing to the failure of
functional recovery. Astrocytes tile the brain and localize
to all cellular environments, which are the key players in
response to injury [2, 3]. In an environment encompassing
a wide range of neuroinflammatory factors such as IL-1β
induced by central nervous system (CNS) injury, the
astrocytes are transformed as “activated” [4]. The activated
astrocytes produce multiple molecular and morphological
features that have been considered as hallmarks of astrocyte
activation in response to CNS injury by histopathologists
and researchers [5–9]. The most prominent of these hall-
marks are hypertrophy of astrocyte cellular processes and
upregulation of the glial fibrillary acidic protein (GFAP),
which is the main constituent of the intermediate filament
system of adult astrocytes [10]. Several studies have shown
that GFAP upregulation accompanied hypertrophy and
migration of astrocytes after a traumatic brain injury
[11, 12]. Our previous study also confirmed that the
downregulation of GFAP expression could attenuate the
astrocyte activation after brain injury [13], suggesting that
its upregulation is crucial for astrocyte activation.
Sirtuins are mammalian homologs of the Saccharomyces
cerevisiae silent mating type information 2 (Sirt2), which
are members of the class III histone/lysine deacetylase
family. The Sirts use NAD+ as an obligatory co-substrate
to remove an acety1 group from the epsilon amine of
lysine [14, 15]. Sirt1 is the first homologous gene of this
family identified in mammals. Some recent studies have
found that the pharmacological activation or upregulation
of Sirt1 expression showed neuroprotective effects in
several models of neurodegenerative diseases [15–18].
Notably, Sirt1 is widely expressed in the entire adult brain
[19] and involved in the maintenance of brain integrity
regulating activities such as oxidative stress and neuronal
degeneration [20]. However, the underlying roles of
Sirt1 in astrocyte activation after brain injury are yet ill-
understood.
Our previous studies found that mitogen-activated
protein kinase (MAPK) cascades were involved in the
glial activation [13] and resveratrol protects against
striatum neuronal apoptosis induced by a nigrostriatal
pathway injury in mice via MAPK pathway [21]. More-
over, some studies showed that Sirt1 participates in
learning and memory through MAPKs. Sirt1 inhibition
reduced the Ras/ERK1/2 pathway associating with re-
sistance to oxidative damage, suggesting that a correl-
ation between Sirt1 and MAPK pathways to protect
against the central nervous system (CNS) injury through
yet unknown mechanisms [22–25].
Thus, we hypothesize that both the Sirt1 and MAPK
pathways, such as ERK, JNK, and p38, were involved in
regulating the astrocyte activation, and some networks
through yet unknown mechanisms promote the recovery
of neural function via attenuation of the astrocyte activa-
tion. To test this hypothesis, we applied a nigrostriatal
pathway injury in the mouse brain to mimic the traumatic
brain injury in vivo and IL-1β stimulation model to induce
astrocyte activation in vitro. Based on these in vitro and in
vivo models, we analyzed the expression of Sirt1 and p-
ERK, p-JNK, and p-p38 after stimulation or injury and
monitored GFAP expression and astrocytes hyper-
trophy, as well as the interactions between Sirt1 and
MAPK (ERK, JNK, p38MAPK) pathways after manipu-




Human recombinant IL-1β (1 × 109 IU/mg protein) was
purchased from R & D Systems (Jiangsu, China). The
cytokine was prepared as the previous study [4]. Medium,
fetal bovine serum and penicillin-streptomycin solution
were from Gibco-BRL/Thermo Fisher (Co., Ltd., USA);
resveratrol (3,4,5′-trihydroxy-trans-stilbene) and dimethyl
sulfoxide (DMSO) were provided by Sigma-Aldrich Inc.
(St. Louis, MO, USA). U0126, SP600125, and SB203580
from Selleck. cn (Shanghai, China) were dissolved in 0.1%
DMSO, which was used as a solvent control. Primary
antibodies including Sirt1 and mitogen-activated protein
kinases (MAPKs) proteins such as p-ERK, JNK, and p38
MAPK were obtained from CST (Shanghai, China), t-ERK/
JNK/p38 MAPK from Proteintech (Wuhan, China),
GFAP from Millipore (MA, USA), and GAPDH from
Abcam (Shanghai, China). The secondary antibody for
Western blot was HRP-conjugated anti-rabbit lgG from
Zhongshan Company (Shanghai, China). Please contact
the author for more detailed data requests.
Primary culture of mouse cortical astrocytes
Primary astrocytes were prepared from 1-day-old neo-
natal Kunming mice as described previously with some
modifications [26]. Briefly, brain cortical tissues were
dissociated in DMEM supplemented with 10% fetal bo-
vine serum, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin. Cells were incubated at 37 °C for 24 h in 95%
air and 5% CO2. The medium was changed after 5 days
and every 3 days thereafter. The cell cultures were used
9 days after plating. For pure astrocyte culture, astro-
cytes were isolated from culture flasks of confluent glial
cultures by shaking at 250 rpm for 24 h. Astrocytes in
the supernatant were collected by centrifugation at
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1000 rpm for 5 min. Purified astrocytes were seeded
into 24-well plates at 1 × 105 cells/ml. The purity of as-
trocytes was greater than 95% as determined by immu-
nostaining using the marker of astrocyte glial fibrillary
acidic protein (GFAP). The astrocytes were stimulated
with 1 ng/ml IL-1β for the tested time course [4]. Cul-
tures were pretreated with 10 μM U0126 (blocks the
ERK pathway), 10 μM SP600125 (blocks the JNK path-
way), 10 μM SB203580 (blocks the p38MAPK pathway),
or DMSO (as a vehicle) for 30 min in serum-free media
before stimulated with IL-1β.
Animal preparation
All experimental procedures were conducted in conformity
with institutional guidelines for the care and use of
laboratory animals, and protocols were approved by the
Institutional Animal Care and Use Committee (CMU
IACUC) in China Medical University (Shenyang, China).
Male KM mice (CL) 8-week-old (25–30 g) were purchased
from the Animal Department, China Medical University
(Shenyang, China), and kept under a constant environ-
ment (12/12-h light/dark cycle). They were allowed free
access to water and food. All the animals were randomly
assigned into the following group: (i) sham injury, (ii)
brain injury+DMSO, and (iii) brain injury+resveratrol
or MAPK (ERK/JNK/p38MAPK) inhibitors. The resvera-
trol/inhibitors or DMSO was injected intracerebroventri-
cularly 30 min prior to brain injury, respectively, including
3 μg/μl resveratrol [27], 400 μM U0126 (ERK inhibitor),
100 μM SP600125 (JNK inhibitor), and SB203580 (p38
kinase inhibitor) following previous studies [25, 28–30].
Behavioral testing
All behavioral tests were performed blindly with respect
to drug administration. The test was conducted prior to
and at 1 and 21 days after injury. Animals were pre-
trained for 3 days for all the tests. Behavioral studies
were repeated two times with three different trials to
validate the behavioral data.
The modified neurological severity score (mNSS) is a
composite test, including motor, sensory, and reflex tests
[31]. A scale of the 0–18 score was graded on the neuro-
logical function wherein the normal score was 0 and a
maximal deficit score was 18. One point was given for the
inability to perform each test or for the absence of a reflex.
Beam walking test—the beam walking test assessed
fine motor coordination and function by measuring the
ability of the animals to traverse an elevated narrow
beam as described previously [32]. The time for the
mouse to cross the beam (not to exceed 60 s) was re-
corded. The measurements were recorded 1 day before
the brain injury (as the baseline) and at each tested
time point after brain injury for all the tests.
For all the tests, three measurements per trial were
recorded 1 day before brain injury (baseline) and at each
tested time point after brain injury.
The model of nigrostriatal pathway injury
The nigrostriatal pathway injury in mouse was used as
the traumatic brain injury model. Briefly, the mice were
fixed in a stereotaxic apparatus (TME Technology Co.,
Ltd., Chengdu, China) with the incisor bar set 3 mm
below the intraaural line under 10% chloral hydrate
(30 mg/kg body weight) anesthesia. The mice were
sheared and sterilized at first. The middle skin was in-
cised on the preshaved scalp, periosteum was cleared
from the cranium, and a small oval hole was made with
a dental drill wherein a 2.0-mm razor blade knife was
inserted [33, 34]. A rectangular gap was drilled at
1.5 mm right back of the bregma, exposing the brain. A
2.0-mm width cutter was fixed in a linear type space
frame, and the tip of the knife was inserted into the
right side of the brain at 0.5 mm lateral to the midline,
1.5 mm posterior to the bregma, and at a depth of
6.0 mm from the surface of the brain. Then, the cutter
was slowly pulled out with hemostatic suture. The skull
was only exposed in the sham group. For all mice, con-
stant temperature operating table was used in the whole
process of brain injury and the room temperature was
controlled approximately at 25 °C in an air-conditioned
room after the brain injury.
Adenovirus construction
To evaluate the potential effect of Sirt1 on activation of
astrocytes in vitro, the astrocytes were transfected with
control or Sirt1 for 24 h and then stimulated with 1 ng/ml
IL-1β. The Sirt1-recombined adenoviral expression vector
and the control vector were constructed (Invitrogen,
Carlsbad, CA, USA) and performed at a multiplicity of in-
fection (MOI) of 20 [35, 36]. The lacZ vector (Invitrogen)
was added to control groups.
Cells (1 × 106) grown to 60–80% confluence in 24 wells
were transfected with adenoviral vectors using a Lipofec-
tamine 2000 kit (Invitrogen, cat. 11668–019) according
to the procedure provided by the manufacturer. The
cells were observed under a fluorescence microscope
and harvested 24 h after transfection.
Western blot
Fresh brain tissues from injured part, which the area up
and down 1 mm from the center of the lesion site in-
cluding the nigrostriatal pathway, were taken and placed
in cool PBS. The cerebral localization states briefly a
rectangular area (2 × 2 mm) is 0.5 mm the posterior,
2.0 mm lateral from the bregma, and 5.5–6.0 mm deep
from the cortex [13]. Western blot analysis was performed
as previously described [37]. Briefly, equal amounts of
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protein (35 mg protein in 20 ml for tissue samples) were
separated by sodium dodecyl sulfate-polyacrylamide gel,
transferred to PVDF membranes (Millipore, US), and
blocked using 5% bovine serum albumin (BSA). The
primary antibodies were rabbit polyclonal anti-Sirt1
(1:1000), p-ERK/JNK/p38MAPK (1:1000), t-ERK/JNK/
p38MAPK (1:2000), and mouse monoclonal anti-GAPDH
(1:5000). All the antibodies were diluted by 5% BSA. In the
following day, a goat anti-rabbit or goat anti-mouse second-
ary antibody (1:5000) labeled by horseradish peroxidase
was added and incubated for 90 min at 37 °C. Bio-Rad was
used for ECL luminescence.
Immunohistochemistry
Immunohistochemical analyses were performed according
to our previous study [13]. Briefly, primary antibodies of
chick anti-GFAP were diluted to 1:500 in 20 mM
phosphate-buffered salines (PBS) and incubated over-
night. In the following day, the sections or the cells
were washed by PBS and cy3 (Jackson ImmunoResearch
Labs, Donkey anti-Chick, 1:100) was added and incubated
for 1 h at 37 °C. After washing by PBS, the fluorescence
quenching agent was used to cover the slices. Fluorescent
microscope (HMS Nikon Imaging Center, ECLIPSE 80i,
Japan) was used to observe and a CCD spot camera was
employed to collect photos. The photos were saved as
TIF and processed by Adobe Photoshop 7.0 (Adobe
Photoshop CS2).
Quantification and statistics
In the quantitative statistics of Western blot, the detection
of gray value in p-ERK/JNK/p-38 bands used computer-
assisted imaging analysis system (Bio-Rad) by drawing a
rectangle with the same size to detect gray value of p-
ERK/JNK/p-38 proteins. Because the total ERK/JNK/p-38
level did not change after the nerve injury, the gray level
ratio of p-ERK and t-ERK, p-JNK and t-JNK, p-p38
MAPK and p38 MAPK, and the ratios of Sirt1 and GFAP
to GAPDH were used as the relative expression level of
the target protein. All the experiments were repeated for
at least three times. Data are presented as the mean and
standard error of the mean (mean ± SEM). The compari-
son of different groups was analyzed by one-way ANOVA
followed by the post hoc Bonferroni evaluation using
GraphPad Prism5. Differences were termed statistically
significant at P < 0.05.
Results
IL-1β-stimulated model and stab brain injury model could
induce astrocyte activation
As shown in Fig. 1a, compared to the control astrocytes,
the GFAP expression was significantly increased within
0.5 h of IL-1β stimulation, indicating IL-1β-induced
astrocyte activation. Compared with the control, the
GFAP-positive astrocytes begin to proliferate with pheno-
typic changes and cell hypertrophy and the characteristics
of the latter depend on the increased expression of GFAP
in 1- and 4-day groups after IL-1β stimulation (Fig. 1c). In
vivo, the protein level of GFAP was significantly increased
at 1 and 4 days after brain injury. Compared with the
sham group, the astrocytes became thicker and cell hyper-
trophy was noticeable around the lesion site at 1 and
4 days after brain injury (Fig. 1d). These results indicated
that brain injury could induce astrocyte activation around
the lesion site.
IL-1β-stimulated model and stab brain injury model could
reduce the expression of Sirt1 and induce the activation
of MAPK pathways
The results showed that the treatment with IL-1β signifi-
cantly reduced the expression of Sirt1 protein from 0.5 h
to 4 days. Concurrently, the ERK, JNK, and p38MAPK
pathways were activated from 0.5 h and continued until
4 days. In addition, we also found that the p-ERK, p-
JNK, and p-p38 proteins were at a high level within
1 day (Fig. 2a).
Compared with the sham group, the expression of
Sirt1 in the injured groups was significantly decreased
from 0.5 h to 4 days after brain injury (Fig. 2; P < 0.01
for all the evaluated time points). ERK, JNK, and
p38MAPK pathways were activated significantly from
0.5 h and lasted for 4 days after brain injury compared
with sham groups (P < 0.01 for all the evaluated time
points). These results revealed that Sirt1 and MAPK
pathways including ERK, JNK, and p38MAPK were also
involved in the mechanism of astrocyte activation in-
duced by brain injury, which was consistent with the in
vitro results.
Sirt1 overexpression by transfected Sirt1 or
pharmacological agonist resveratrol decreased the
astrocyte activation in vitro and in vivo
The results revealed that the primary astrocytes trans-
fected with Sirt1 appeared to elevate the Sirt1 expression
and decrease the GFAP expression significantly as com-
pared to those transfected with control vector after 24 h
(Fig. 3a). As shown in Fig. 3c. As compared to the trans-
fection with control, the Sirt1-transfected astrocytes
showed fewer signs of cell hypertrophy and were similar
to the control group.
As shown in Fig. 3b, as compared to pretreating with
DMSO, pretreatment with resveratrol significantly in-
creased the expression of Sirt1 at 1 day and reduced
the expression of GFAP at 4 day after brain injury. Im-
munofluorescence staining revealed that resveratrol
could remarkably improve the signs of astrocyte hyper-
trophy around the lesion site (Fig. 3d). The results
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suggested that Sirt1 might function as a protective factor
for astrocyte overactivation after brain injury in vivo.
Sirt1 overexpression upregulated ERK activation and
downregulated JNK and p38MAPK activation induced by
IL-1β-stimulation in vitro and brain injury in vivo
Compared with the transfection control, the results
showed that transfected Sirt1 markedly upregulated the
p-ERK expression and downregulated the p-JNK and p-
p38MAPK expressions at 1 day after IL-1β stimulation
in astrocytes (all P < 0.05; Fig. 4a). This suggested potential
interactions between Sirt1 and MAPKs regulating the
astrocyte activation induced by IL-1β stimulation.
The expressions of p-ERK, p-JNK, and p-p38 at
1 day after brain injury were shown in Fig. 4b. When
the resveratrol-treated group significantly elevated the
Sirt1 expression (P < 0.01; Fig. 3b), p-ERK expression
was markedly increased and p-JNK/p-p38 MAPK ex-
pressions were reduced (P < 0.05 for p-ERK, P < 0.01
for p-JNK and p-p38MAPK; Fig. 4b), as compared to
the treatment with DMSO in mice after brain injury.
The results indicated that Sirt1 mediated the expres-
sion of ERK, JNK, and p-38MAPK pathways after
mechanical brain injury in vivo.
The effects of inhibitors of MAPK pathways on ERK/JNK/
p38 activation
As shown in Fig. 5a, when the ERK activation was inhibited
by U0126, the JNK and p38 MAPK activation were not
affected. Similarly, SP600125 or SB203580 could inhibit the
JNK activation or p38MAPK activation, respectively, but
did not affect the other two pathways.
The results showed that U0126 significantly inhibited
the ERK activation but exerted no effect on the JNK or
Fig. 1 Both the IL-1β stimulation and brain injury could induce the astrocyte activation. a Western blot showed that the GFAP expression after
IL-1β stimulation, *P < 0.05 and **P < 0.01 vs. the control group, the control group: control without IL-1β stimulation. b The GFAP expression was
showed after brain injury, *P < 0.05 and **P < 0.01 vs. the sham group. We also detected changes in astrocyte morphology by immunofluorescence
staining in vitro; the GFAP-positive astrocytes were green (c) and in vivo and the GFAP-positive astrocytes were red (d) at 1 and 4 days, respectively.
Scale bar = 50 μm
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p38MAPK activation in comparison to the DMSO injec-
tion (P < 0.05 for ERK; P > 0.05 for JNK and p38MAPK;
Fig. 5b). Similarly, P600125 significantly inhibited the
JNK activation without affecting the ERK or p38MAPK
activation as compared to the DMSO injection (P < 0.05
for JNK; P > 0.05 for ERK and p38MAPK; Fig. 5b).
SB203580 significantly inhibited the p38MAPK activa-
tion but showed no effects on ERK or JNK activation as
compared to DMSO injection (P < 0.05 for p38MAPK;
P > 0.05 for ERK and JNK; Fig. 5b).
Inhibiting ERK, JNK, or p38MAPK pathway activation
elevated Sirt1 expression and attenuated astrocyte
activation in vitro and in vivo
As shown in Fig. 6a, when the ERK, JNK, or p38MAPK
pathway was inhibited at 1 day after IL-1β stimulation,
the protein level of Sirt1 was significantly elevated in the
primary astrocytes treated with the inhibitor as com-
pared with the treatment with DMSO (P < 0.05 for
U0126 and SB203580; P < 0.01 for SP600125). Moreover,
Western blot demonstrated that the inhibition of ERK,
JNK, or p38MAPK pathway significantly suppressed the
GFAP protein level at 4 day after IL-1β stimulation in
primary astrocytes (P < 0.01 for all; Fig. 6a). However,
the DMSO control did not show any effect on GFAP
protein level as compared to the primary astrocytes
stimulated with IL-1β (P > 0.05, data not shown).
To further substantiate the in vitro finding, a stab
wound brain injury was employed. When the ERK, JNK,
or p38MAPK pathway was inhibited, the expression of
Sirt1 was significantly elevated (P < 0.05 for all the inhib-
itors; Fig. 6b) and the GFAP level was attenuated as
compared to DMSO (P < 0.05 for SB203580; P < 0.01 for
U0126 and SP600125; Fig. 6b). We also detected a sig-
nificant suppression of astrocyte hypertrophy and GFAP
staining by immunofluorescence in vitro and in vivo
(Fig. 6c, d).
Elevating Sirt1 expression and inhibiting ERK, JNK, or
p38MAPK pathway activation improved the
neurobehavioral function after brain injury
As shown in Fig. 7a, the mean mNSS was significantly
reduced in the resveratrol group (from 1 to 21 days all
P < 0.05), U0126 group (from 4 to 21 days, P < 0.05),
SP600125 group (from 7 to 21 days, P < 0.05), and
SB203580 group (from 7 to 21 days, P < 0.05) as com-
pared to the DMSO group. Moreover, the beam walk
performances also showed significantly reduced latency
to cross the beam from 4 to 21 days after injury (from
4 to 21 days, P < 0.05 for the resveratrol group; from 7
to 21 days, P < 0.05 for the U0126 group; from 7 to
21 days, P < 0.05 for the SP600125 group; from 7 to
21 days, P < 0.05 for the SB203580 group; Fig. 7b) as
compared to the DMSO group.
Fig. 2 The expression of Sirt1 and p-ERK/p-JNK/p-p38 after IL-1β stimulation and brain injury. The expression of Sirt1 is reduced and p-ERK, p-JNK, and
p-p38 are elevated significantly for the time indicated in vitro (a) and in vivo (b). n = 6/group, *P < 0.05 and **P < 0.01 vs. the control or sham group
Li et al. Journal of Neuroinflammation  (2017) 14:67 Page 6 of 13
Discussion
Astrocyte activation is presumed to depress neuronal
regeneration after CNS injury due to the glial scar, a
formation of a physical barrier, and overproduction of
multiple proinflammatory cytokines, including IL-1β,
IL-6, and TNFα, which further aggravate the glial acti-
vation and injure the remaining neurons through posi-
tive feedback [4, 31, 38, 39]. The recombinant IL-1β
used in the present study was shown to be biologically
active as previously demonstrated by its ability to induce
astrocyte activation in an in vitro astrocyte activation
model [4, 40–42]. Therefore, we speculate that our IL-1β
stimulation model is suitable and credible for the detec-
tion of the astrocyte activation in vitro. Upregulation of
GFAP and hypertrophy of astrocyte cellular processes
play a major and prominent role in astrocyte activation
and the formation of glial scar [6, 12]. In the present
study, the IL-1β stimulation triggered an elevated level
of GFAP and induced the astrocyte hypertrophy; this
phenomenon was confirmed by the lesion site in a trau-
matic brain injury. The rational design of therapeutic in-
terventions for CNS injury could be contingent critically
Fig. 3 Overexpression of Sirt1 attenuates astrocyte activation in vitro and in vivo. Overexpression of Sirt1 significantly reduced GFAP expression
compared with transfection control in vitro (a), n = 6/group, **P < 0.01 vs. the control group; ##P < 0.01 vs. IL-1β-con; and in vivo (b), *P < 0.05 and
**P < 0.01 vs. the sham group; #P < 0.05 and ##P < 0.01 vs. the DMSO group. Immunofluorescence staining revealed that overexpression of Sirt1
improved the signs of astrocyte hypertrophy by immunodetection of GFAP in vitro (c, green) and in vivo (d, red)
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upon a comprehensive understanding of the process of
astrocyte activation, thereby necessitating an exploration
of the mechanism of GFAP upregulation and astrocyte
cellular hypertrophy after brain injury.
In recent years, Sirt1 has emerged as a strategy for
the treatment of multiple neurodegenerative disorders
[25, 43–46]. Although highly expressed in the brain,
Sirt1 is also known to localize in the neurons and glial
cells among various cell types [47–50]. In addition, in-
vestigators found that the expression of Sirt1 varies in
different tissues or cell types’ response to injury; some
supported that the injury could induce Sirt1 activation
and upregulate its expression [17, 25, 51], and others
showed that Sirt1 expression was downregulated after
the injury [52]. In the present study, we reported that
the expression of Sirt1 was downregulated after brain
injury in vivo; a similar result was obtained in primary
astrocytes after stimulation with IL-1β in vitro. More-
over, the administration of resveratrol, a pharmaco-
logical Sirt1 agonist, attenuated astrocyte activation by
decreasing the GFAP expression and improving the cell
morphology in vivo. The overexpression of Sirt1 in pri-
mary astrocytes transfected with lentiviral vector Sirt1
in vitro also generated a similar result. The evidence
suggests that Sirt1 expression was involved in the set-
ting of astrocyte activation after injury in vivo or stimu-
lation in vitro, which strongly supports the mechanism
of the neuroprotective effect of Sirt1.
Previous study showed that overactivated astrocyte
requires energy from mitochondrial biogenesis and the
overenhanced mitochondrial respiration in astrocytes
limits the substrate supply from astrocytes to neurons
[53]. Recently, it was suggested that neurons can release
and transfer damaged mitochondria to astrocytes for
Fig. 4 The effects of Sirt1 overexpression on regulation of p-ERK/p-JNK/p-p38 in vitro and in vivo. a Overexpression of Sirt1 upregulates p-ERK
and downregulates p-JNK and p-p38 compared to transfection control in vitro. n = 6/group, **P < 0.01 vs. the control group; #P < 0.05 vs. IL-1β-con. b
Elevated Sirt1 expression increased ERK activation and decreased JNK and p-38 activation in vivo. n = 6/group, **P < 0.01 vs. the sham group; #P < 0.05
and ##P < 0.01 vs. the DMSO group
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disposal and recycling [54]. Mitochondrial function may
be essential for these neuroglial protective mechanisms
because damage of astrocytic mitochondria makes neurons
vulnerable to cell death [55]. It may be surmised that in-
creased mitochondrial function could support the function-
ality of astrocytes. As one of the major targeting organelles
of Sirt1 (through PGC1α), mitochondrial function would
be a highly possible candidate connection in neuropro-
tection of Sirt1. Resveratrol, one of the Sirt1 agonists,
improves mitochondrial function and protects against
metabolic disease by activating Sirt1 and PGC-1α [56].
In this study, we found that increased Sirt1 expression
could attenuate the astrocyte activation and improve
the neurobehavioral function after brain injury, the
mechanism of which may be related to effects of Sirt1
on mitochondrial function in astrocytes. Further experi-
ments are needed to verify this hypothesis.
After brain injury, MAPK family, including ERK, JNK,
and p38MAPK, are highly expressed and inhibiting either
of the cascades could alter the outcome of the brain injury
[13, 57–61]. Though the ERK, JNK, and p38MAPK activa-
tion are proven to participate in a variety of injuries in
vitro and in vivo, the roles of these three cascade activa-
tion in astrocyte stimulation in vivo and in vitro are yet
controversial, which leads to the difficulties in exploring
their effects on the mechanism of brain injury. Initially,
our previous study has shown disparate roles of ERK
stimulation in glial activation after brain injury in vivo
[13]; however, some studies demonstrated that ERK ac-
tivation also contributed to neuroprotection [62, 63].
Gao et al. (2013) identified that the inhibition of JNK,
but not ERK and p38, suppressed GFAP upregulation in
an astrocyte-scratched injury model in vitro, implying that
JNK was involved in regulating astrocyte activation under
physiological conditions. Several studies demonstrate that
p38MAPK also mediates the expression of GFAP and
various astrocyte-regulated molecules in vivo and in
vitro [64–67]. In this study, we applied the inhibitors of
Fig. 5 The effects of inhibitors U0126, SP600125, and SB203580 on ERK, JNK, and p38 activation. a U0126, SP600125, and SB203580 (10 μM)
significantly inhibited ERK, JNK, and p38MAPK activation respectively in vitro. n = 6/group, **P < 0.01 vs. the DMSO group. b U0126 (200 μM),
SP600125, and SB203580 (100 μM) significantly inhibited ERK, JNK, and p38MAPK activation respectively around the lesion site in vivo. n = 6/
group, **P < 0.01 vs. the DMSO group
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Fig. 6 Inhibiting MAPK pathway activation increases Sirt1 expression and alleviates astrocyte activation. a Levels of Sirt1 and GFAP protein in
primary astrocytes after IL-1β stimulation in vitro. b Inhibiting MAPK pathway activation significantly increases Sirt1 expression but alleviates GFAP
expression in vivo. n = 6/group, *P < 0.05 and **P < 0.01 vs. the DMSO group. Immunofluorescent image of GFAP in vitro and in vivo was showed
in (c) and (d). Scale bar = 50 μm
Fig. 7 The neuroprotection in mice pretreated with resveratrol to elevate Sirt1 expression or inhibitors to inhibit MAPK pathway activation. a The
mNSS significantly reduced in mice with resveratrol and inhibitor groups. b Beam latency showed that resveratrol and inhibitor groups significantly
decreased the time of mice to cross the beam compared to the DMSO group after brain injury. Values are showed as mean ± SEM. n = 6/
group, *P < 0.05 vs. the DMSO group
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ERK, JNK, and p38 to inhibit the expression of p-ERK, p-
JNK, or p-p38, which could, in turn, suppress the GFAP
upregulation and improve the cell hypertrophy.
Moreover, Zhao et al. (2012) showed that Sirt1 down-
regulation induced by the pharmacological inhibitor
salermide or RNA interference could attenuate the acti-
vation of ERK after brain injury. In addition, the inhib-
ition of ERK activation could also decrease the Sirt1
expression, suggesting that there may be some interac-
tions between Sirt1 and MAPK cascade activation.
In the present study, inhibition of ERK or JNK or p38
phosphorylation significantly upregulated the expression
of Sirt1 and decreased the expression of GFAP in cul-
tured cortical astrocytes and mice brain. The improved
neurobehavioral function in ERK inhibitor, JNK inhibi-
tor, or p38 inhibitor group indicated that these neuro-
protective effects might be associated with alleviating
the astrocyte activation. Interestingly, when the MAPK
cascade activation was inhibited, the Sirt1 expression
was significantly upregulated; however, when the overex-
pression of Sirt1 by pharmacological agonist (resveratrol)
or Sirt1 interference was inhibited, the ERK activation was
increased and the JNK and p38 activation were inhibited.
These results further ravel some interactions between
Sirt1 and MAPK activation after brain injury, although the
precise mechanism remains to be further elucidated.
Herein, we have summarized the plausible dynamic
relationship between Sirt1 and MAPK (ERK, JNK, and
p38MAPK) pathways using a brain injury model in Fig. 8.
The brain injury and IL-1β stimulation reduced Sirt1
and activated MAPK pathway leading to the astrocyte
activation. The overexpression of Sirt1 by agonist or
transfection-attenuated astrocyte activation regulated
the MAPK pathway activation. The inhibition of MAPK
pathway activation improved the astrocyte activation
and elevated Sirt1 expression. Sirt1 interacted with
MAPK activation via a synergic relationship to regulate
astrocyte activation induced by brain injury in vivo or
IL-1β stimulation in vitro, showing that both Sirt1 and
MAPK pathways are potentially attractive therapeutic
targets in the therapy of neurodegeneration induced by
astrocyte activation. Thus, a new pharmacological
product or endogenous method which could signifi-
cantly elevate Sirt1 expression or activity might be a
novel and efficient strategy for neuroprotection after
brain injury.
Conclusions
In summary, this study found that Sirt1 is an import-
ant topic for astrocyte activation induced by IL-1β
stimulation in vitro and traumatic brain injury in vivo;
inhibition of ERK, JNK, or p38MAPK activation sup-
pressed GFAP upregulation and improved the cell
hypertrophy to attenuate the astrocyte activation; Sirt1
interacted with ERK pathway activation via a synergic
way, but an antergic way with JNK and p38MAPK
pathway activation to mediate the expression of GFAP
and astrocyte morphology that is the astrocyte activa-
tion. Investigation of the regulation and levels of these
and other signaling molecules may be a novel and ef-
fective strategy for neuroprotection after brain injury.
Fig. 8 The possible interactions between Sirt1 and ERK, JNK, or p38MAPK pathway in traumatic brain injury. The brain injury reduced endogenous
Sirt1 level and activated ERK, JNK, and p38MAPK pathways. Overexpressed Sirt1 attenuated astrocyte activation and decreased ERK, JNK, and
p38MAPK activation. Inhibition of ERK, JNK, or p38MAPK activation increased Sirt1 expression and attenuated astrocyte activation
Li et al. Journal of Neuroinflammation  (2017) 14:67 Page 11 of 13
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